A G Favaretto

Summary

Affiliation: University Hospital
Country: Italy

Publications

  1. ncbi request reprint Second and third line treatment in advanced non-small cell lung cancer
    Adolfo G Favaretto
    Oncologia Medica II, Istituto Oncologico Veneto IRCCS, Padova 35128, Italy
    Discov Med 8:204-9. 2009
  2. doi request reprint Second and third line treatment in non-small cell lung cancer
    Adolfo Favaretto
    U O Oncologia Medica 2, Istituto Oncologico Veneto IOV IRCCS, Via Gattamelata 64, 35128 Padova, Italy
    Crit Rev Oncol Hematol 71:117-26. 2009
  3. ncbi request reprint Non-platinum combination of gemcitabine in NSCLC
    A G Favaretto
    Medical Oncology Department, Azienda Ospedaliera di Padova, Padova, Italy
    Ann Oncol 17:v82-5. 2006
  4. ncbi request reprint Overview on ongoing or planned clinical trials in Europe
    Adolfo Favaretto
    University Hospital, Medical Oncology Department, Via Gattamelata, 64, Padova, Italy
    Lung Cancer 49:S117-21. 2005
  5. ncbi request reprint Neoadjuvant moderately high-dose chemotherapy with rh-G-CSF in locally advanced breast carcinoma
    A Fornasiero
    Division of Medical Oncology, Azienda Ospedaliera di Padova, Padua, Italy
    Tumori 87:223-8. 2001
  6. ncbi request reprint Pemetrexed single agent in previously treated non-small cell lung cancer: a multi-institutional observational study
    Alessandra Bearz
    Medical Oncology A, IRCCS CRO, Via Franco Gallini 2, 33081 Aviano, Italy
    Lung Cancer 60:240-5. 2008
  7. ncbi request reprint Cisplatin plus gemcitabine or vinorelbine for elderly patients with advanced non small-cell lung cancer: the MILES-2P studies
    Cesare Gridelli
    Division of Medical Oncology, S G Moscati Hospital, Avellino, Italy
    J Clin Oncol 25:4663-9. 2007
  8. ncbi request reprint Factorial phase III randomised trial of rofecoxib and prolonged constant infusion of gemcitabine in advanced non-small-cell lung cancer: the GEmcitabine-COxib in NSCLC (GECO) study
    Cesare Gridelli
    Medical Oncology, S Giuseppe Moscati Hospital, Avellino, Italy
    Lancet Oncol 8:500-12. 2007
  9. ncbi request reprint Single-agent pemetrexed or sequential pemetrexed/gemcitabine as front-line treatment of advanced non-small cell lung cancer in elderly patients or patients ineligible for platinum-based chemotherapy: a multicenter, randomized, phase II trial
    Cesare Gridelli
    Division of Medical Oncology, S G Moscati Hospital, Avellino, Italy
    J Thorac Oncol 2:221-9. 2007
  10. ncbi request reprint Chemotherapy for elderly patients with advanced non-small-cell lung cancer: the Multicenter Italian Lung Cancer in the Elderly Study (MILES) phase III randomized trial
    Cesare Gridelli
    J Natl Cancer Inst 95:362-72. 2003

Collaborators

Detail Information

Publications16

  1. ncbi request reprint Second and third line treatment in advanced non-small cell lung cancer
    Adolfo G Favaretto
    Oncologia Medica II, Istituto Oncologico Veneto IRCCS, Padova 35128, Italy
    Discov Med 8:204-9. 2009
    ..Many trials are ongoing to assess the activity of new drugs, alone or in combination with other agents, or new combinations of third-generation chemotherapeutic agents...
  2. doi request reprint Second and third line treatment in non-small cell lung cancer
    Adolfo Favaretto
    U O Oncologia Medica 2, Istituto Oncologico Veneto IOV IRCCS, Via Gattamelata 64, 35128 Padova, Italy
    Crit Rev Oncol Hematol 71:117-26. 2009
    ..Many trials are ongoing to assess the activity of new drugs, alone or in association, and new combinations of third-generation chemotherapeutic agents...
  3. ncbi request reprint Non-platinum combination of gemcitabine in NSCLC
    A G Favaretto
    Medical Oncology Department, Azienda Ospedaliera di Padova, Padova, Italy
    Ann Oncol 17:v82-5. 2006
  4. ncbi request reprint Overview on ongoing or planned clinical trials in Europe
    Adolfo Favaretto
    University Hospital, Medical Oncology Department, Via Gattamelata, 64, Padova, Italy
    Lung Cancer 49:S117-21. 2005
    ..Pemetrexed has influenced not only the clinical practice, but also the patient enrolment in clinical trials...
  5. ncbi request reprint Neoadjuvant moderately high-dose chemotherapy with rh-G-CSF in locally advanced breast carcinoma
    A Fornasiero
    Division of Medical Oncology, Azienda Ospedaliera di Padova, Padua, Italy
    Tumori 87:223-8. 2001
    ..3%). CONCLUSIONS: The 14-day regimen was well tolerated and effective in LABC patients, although not superior to standard-dose chemotherapy. To improve results the use of new drugs in controlled clinical trials seems warranted...
  6. ncbi request reprint Pemetrexed single agent in previously treated non-small cell lung cancer: a multi-institutional observational study
    Alessandra Bearz
    Medical Oncology A, IRCCS CRO, Via Franco Gallini 2, 33081 Aviano, Italy
    Lung Cancer 60:240-5. 2008
    ..We evaluated the activity and toxicity of Pemetrexed, in a post-registration phase, to assess whether clinical benefits justify its employment in a second-line setting in routine clinical practice...
  7. ncbi request reprint Cisplatin plus gemcitabine or vinorelbine for elderly patients with advanced non small-cell lung cancer: the MILES-2P studies
    Cesare Gridelli
    Division of Medical Oncology, S G Moscati Hospital, Avellino, Italy
    J Clin Oncol 25:4663-9. 2007
    ..Two phase I/II trials were done to evaluate the feasibility of cisplatin combined with gemcitabine or vinorelbine in elderly patients with advanced non-small-cell lung cancer (NSCLC)...
  8. ncbi request reprint Factorial phase III randomised trial of rofecoxib and prolonged constant infusion of gemcitabine in advanced non-small-cell lung cancer: the GEmcitabine-COxib in NSCLC (GECO) study
    Cesare Gridelli
    Medical Oncology, S Giuseppe Moscati Hospital, Avellino, Italy
    Lancet Oncol 8:500-12. 2007
    ..We aimed to assess whether the addition of rofecoxib or PCI gemcitabine could improve overall survival compared with first-line treatment with cisplatin plus gemcitabine given by standard infusion...
  9. ncbi request reprint Single-agent pemetrexed or sequential pemetrexed/gemcitabine as front-line treatment of advanced non-small cell lung cancer in elderly patients or patients ineligible for platinum-based chemotherapy: a multicenter, randomized, phase II trial
    Cesare Gridelli
    Division of Medical Oncology, S G Moscati Hospital, Avellino, Italy
    J Thorac Oncol 2:221-9. 2007
    ....
  10. ncbi request reprint Chemotherapy for elderly patients with advanced non-small-cell lung cancer: the Multicenter Italian Lung Cancer in the Elderly Study (MILES) phase III randomized trial
    Cesare Gridelli
    J Natl Cancer Inst 95:362-72. 2003
    ..We compared the effectiveness and toxicity of the combination of vinorelbine plus gemcitabine with those of each drug given alone in an open-label, randomized phase III trial in elderly patients with advanced NSCLC...
  11. ncbi request reprint Adding gemcitabine to paclitaxel/carboplatin combination increases survival in advanced non-small-cell lung cancer: results of a phase II-III study
    Adriano Paccagnella
    Medical Oncology Department, SS Giovanni and Paolo Hospital, Venezia, Italy
    J Clin Oncol 24:681-7. 2006
    ..We therefore conducted a clinical trial to test if paclitaxel/carboplatin/gemcitabine (PCG) increases overall survival (OS) and response rate (RR) over PC...
  12. ncbi request reprint Pretreatment quality of life and functional status assessment significantly predict survival of elderly patients with advanced non-small-cell lung cancer receiving chemotherapy: a prognostic analysis of the multicenter Italian lung cancer in the elderly s
    Paolo Maione
    S Giuseppe Moscati Hospital, Avellino, Italy
    J Clin Oncol 23:6865-72. 2005
    ..To study the prognostic value for overall survival of baseline assessment of functional status, comorbidity, and quality of life (QoL) in elderly patients with advanced non-small-cell lung cancer treated with chemotherapy...
  13. pmc Supportive care in patients with advanced non-small-cell lung cancer
    M Di Maio
    National Cancer Institute Clinical Trials Unit, Naples
    Br J Cancer 89:1013-21. 2003
    ..Chemotherapy does not remarkably affect the pattern of SC, except for some drugs against side effects. Elderly patients assume more drugs for concomitant diseases and receive less antiemetics than adults...
  14. ncbi request reprint Overprotective caregivers of elderly cancer patients: a case report
    Umberto Basso
    Department of Medical Oncology, Azienda Ospedaliera, Istituto Oncologico Veneto, Padua, Italy
    Tumori 92:362-3. 2006
    ..Devoting time to the relatives represents a key element to create a communicative and efficient relationship with older cancer patients...
  15. ncbi request reprint Elderly patients with small cell lung cancer
    Adriano Paccagnella
    Oncology Unit, Venice Hospital
    Tumori 88:S145-7. 2002
  16. ncbi request reprint Platinum-etoposide chemotherapy in elderly patients with small-cell lung cancer: results of a randomized multicenter phase II study assessing attenuated-dose or full-dose with lenograstim prophylaxis--a Forza Operativa Nazionale Italiana Carcinoma Polmona
    Andrea Ardizzoni
    Medical Oncology, Parma University Hospital, Via Gramsci 14, 43100 Parma, Italy
    J Clin Oncol 23:569-75. 2005
    ..We conducted a randomized two-stage phase II study to assess the therapeutic index of two different platinum/etoposide regimens, attenuated-dose (AD) and full-dose (FD) plus prophylactic lenograstim...